Research Grade Briobacept

Description: Briobacept (BS11221) is a research-grade recombinant antibody targeting CD257. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species:
Isotype: Fusion-[TNFRSF13C(tumornecrosisfactorreceptor(TNFR)superfamilymember13C,BAFFR,BR3,Bcellactivatingfactorreceptor,CD268)]2-IGHG1Fc(Fragmentconstant)
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality:
Applications: Research Grade Biosimilar
Target: BAFF,ZTNF4,BLYS,Tumornecrosisfactorligandsuperfamilymember13B,Dendriticcell-derivedTNF-likemolecule,TALL-1,TNF-andAPOL-relatedleukocyteexpressedligand1,BLyS,Blymphocytestimulator,TNFSF13B,CD257,TNFSF20,TALL1,B-cell-activatingfactor
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: BR3-Fc,SS-79,CAS:869881-54-9
Background: Tumor necrosis factor ligand superfamily member 13B (CD257/BAFF) is a ~31 kDa protein. Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response.
Note: For research use only. Not suitable for clinical or therapeutic use.